ALT Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Altimmune, Inc

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

9 days ago - By: Altimmune, Inc

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

10 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

11 days ago - By: Altimmune, Inc

Altimmune to Participate in Two Upcoming Investor Conferences

13 days ago - By: Altimmune, Inc

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

a month ago - By: Benzinga

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

17 days ago - By: Altimmune, Inc

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

a month ago - By: Altimmune, Inc

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

a month ago - By: Grabar Law Office - Mentions: FIVE FLYW HTZ

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

a month ago - By: Bragar Eagel & Squire

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

a month ago - By: Faruqi & Faruqi, LLP

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

a month ago - By: Bragar Eagel & Squire

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

a month ago - By: Levi & Korsinsky, LLP

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders

a month ago - By: Faruqi & Faruqi LLP

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

a month ago - By: Bragar Eagel & Squire

ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

a month ago - By: Faruqi & Faruqi, LLP

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

2 months ago - By: THE ROSEN LAW FIRM, P. A.

ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

2 months ago - By: Berger Montague

Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit

2 months ago - By: The Rosen Law Firm PA

ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

2 months ago - By: DJS Law Group

Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT

2 months ago - By: Faruqi & Faruqi LLP

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

2 months ago - By: Berger Montague

DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025

2 months ago - By: Bragar Eagel & Squire

ALTIMMUNE (ALT) DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Before the October 6th Deadline in the Altimmune Class Action Lawsuit

2 months ago - By: THE ROSEN LAW FIRM, P. A.

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

2 months ago - By: The Gross Law Firm

Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT

2 months ago - By: Altimmune, Inc

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

2 months ago - By: The Rosen Law Firm PA

ALT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

ALTIMMUNE INC (ALT) Stock News

ALT Latest News, Press Relases and Analysis